ClinicalTrials.gg
RecruitingNCT07545122CT-202Updated Nov 16, 2026

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

A Phase 1 interventional study of CT-202 in Triple Negative Breast Cancer (TNBC), Colorectal Cancer and Urothelial Cancer, sponsored by Context Therapeutics Inc.. Recruiting at 6 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Context Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 8, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Triple Negative Breast Neoplasms with a site in Australia — 30 open to participants now, 48 under way, 9 of them phase 3. Triple Negative Breast Neoplasms · Australia.

Planned enrollment
42nd of 93
162 · median 139
Started
2026
with 6 others
Phase 1
44 of 94
13 open now
Primary completion
2030-01
later than 41 of 47 live
Registered
91st of 94
by date

Among the 94 studies in Triple Negative Breast Neoplasms with a site in Australia, this one is the 42nd largest by planned enrollment of the 93 interventional ones that give a count, is one of 7 that started in 2026, is one of 44 in phase 1, reaches primary completion later than 41 of the 47 other live ones, and was the 91st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

30 of the 94 studies in Triple Negative Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Triple Negative Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.

Read the detailed description

Phase 1a Dose Escalation: Will follow a Bayesian Optimal Interval (BOIN) design (Liu, 2015) with step up dosing (i.e. priming followed by full doses of CT-202), Q2W administration schedule, and approximately 6 dose levels. Participants will continue study treatment until confirmed disease progression, the occurrence of unacceptable toxicity, withdrawal from the study or decision to discontinue treatment by the investigator.

Phase 1b Dose Expansion: Upon completion of the dose escalation Phase 1a, CT-202 may be evaluated at 2 or more dose levels and 2 or more dosing schedules in at least 4 but up to 6 expansion cohorts. The population(s) will include participants with the same tumor indications, or subsets, evaluated in the dose escalation phase (TNBC, CRC, or UC). Up to 15 participants will be assigned to each dosing cohort.

Based on the totality of data from Phase 1b, a RP2D for future clinical studies will be determined.

03

Conditions studied

  • Triple Negative Breast Cancer (TNBC)
  • Colorectal Cancer
  • Urothelial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies
  • Participants with per 1.1
  • 0, 1, or 2 and of ≥ 12 weeks
  • Participants have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • History of severe skin toxicity
  • Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.
  • Concurrent participation in another clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Phase 1a

    Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation.

    Drug: CT-202

  • Experimental
    Phase 1b

    Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202

    Drug: CT-202

Interventions

  • DrugCT-202

    Nectin-4 bispecific

06

What researchers measure

Primary outcomes

  1. Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)

    Phase 1a will evaluate increasing doses of CT-202 based on the assessment of DLTs

    Time frame: From date of first dose of CT-202 until 28 days following the first dose

  2. Phase 1b: Overall response rate (ORR)

    ORR will be based on the overall response rate as assessed by Investigators according to RECIST v1.1

    Time frame: From date of first dose of CT-202until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

07

Study locations

6 of 6 sites recruiting
  • Sydney Adventist Hospital
    Wahroonga, New South Wales 2076, Australia
    Recruiting
  • Crown Princess Mary Cancer Centre Westmead Hospital
    Westmead, New South Wales, Australia
    Recruiting
  • Tasman Oncology Research
    Gold Coast, Queensland, Australia
    Recruiting
  • Calvary Mater Hospital Newcastle
    Newcastle, Queensland, Australia
    Recruiting
  • Olivia Newton John Cancer Centre
    Heidelberg, Victoria, Australia
    Recruiting
  • Linear Clinical Research
    Perth, Western Australia, Australia
    Recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2030, 40 months after the start.

Of 136 industry-sponsored phase 1 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 70. This study's planned 40 months is below that.

Counting every sponsor, half of 209 studies reached it within 54 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 22, 2026
StartActual
Sep 3, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Australia)
  • Crown Princess Mary Cancer Centre Westmead Hospital · Westmead, Australia
  • Olivia Newton John Cancer Centre · Heidelberg, Australia
Oct 8, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  2. Oct 8, 2026
    2 sites added
    Show 2 added (2 Australia)
    • Crown Princess Mary Cancer Centre Westmead Hospital · Westmead, Australia
    • Olivia Newton John Cancer Centre · Heidelberg, Australia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07545122
Lead sponsor
Context Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Sep 3, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Context Clinical Development
Contact
Cntx-ct202-101@contexttherapeutics.com
267.225.7416

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion